A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea

Study acronym: Opsynvi RMP
StatusNot Yet Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Johnson & Johnson
290 trials monitored
See 16 trials at risk
Hypertension
1,945 trials monitored
See 101 trials at risk
The purpose of this study is to evaluate how safe Opsynvi (macitentan/tadalafil fixed-dose combination) is in adult participants with pulmonary arterial hypertension under routine clinical practice in Korea. Pulmonary arterial hypertension is a condition where the blood vessels that carry blood from the heart to the lungs become narrowed or stiff.
Trial Details
NCT Number NCT07890285
Lead Sponsor Janssen Korea, Ltd., Korea
Conditions
(from sponsor)		 Pulmonary Arterial Hypertension
Related terms Pulmonary Arterial Hypertension
Enrollment 333 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov